Inovio Pharmaceuticals, Inc. (INO) - What Are Analysts Saying About This Stock?

Inovio Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is “Moderate Buy”: Four of six covering brokerages rate INO a buy, one rates it hold and one sell. The average 1-year price target is $6.33.
  • Recent rating changes were mixed: Piper Sandler cut its price target to $6 from $8 while maintaining an overweight rating; HC Wainwright reaffirmed a buy rating with a $5 target.
  • Inovio missed quarterly expectations: It reported a loss of $0.50 per share versus consensus estimates of a $0.21 loss, and revenue of $0.30 million versus estimates of $2.27 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned an average rating of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.33.

Several equities analysts have weighed in on INO shares. Wall Street Zen upgraded Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Inovio Pharmaceuticals in a research note on Thursday, November 12th. Piper Sandler reiterated an "overweight" rating and set a $6.00 price objective (down from $8.00) on shares of Inovio Pharmaceuticals in a research report on Wednesday, November 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Inovio Pharmaceuticals in a research note on Wednesday, November 11th. Finally, Zacks Research cut shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 12th.

Read Our Latest Stock Analysis on INO

Inovio Pharmaceuticals Trading Up 2.9%

Shares of INO opened at $1.76 on Friday. The business's 50 day moving average is $1.21 and its 200 day moving average is $1.27. The company has a market capitalization of $193.92 million, a PE ratio of -3.26 and a beta of 1.71. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.29). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $2.27 million. Equities research analysts predict that Inovio Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Eversept Partners LP bought a new stake in Inovio Pharmaceuticals during the first quarter worth approximately $1,802,000. HighTower Advisors LLC raised its position in Inovio Pharmaceuticals by 104.8% during the third quarter. HighTower Advisors LLC now owns 26,076 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 13,346 shares during the period. Virtu Financial LLC purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter worth approximately $114,000. RA Capital Management L.P. purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter worth approximately $8,809,000. Finally, Greenwich Wealth Management LLC increased its position in shares of Inovio Pharmaceuticals by 38.4% during the 3rd quarter. Greenwich Wealth Management LLC now owns 44,299 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 12,300 shares during the last quarter. Institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body's immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company's technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Featured Stories

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?

Before you consider Inovio Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.

While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines